When examining the latest trends in the treatment of Alzheimer, the paradigm has been shifted to immunotherapy through the activation of macrophage in the brain from the present target therapy in which accumulation of amyloid  or tau protein phosphorylation in the brain directly targeted. In particular, the attention of the industry and the academy is paid that when administrating anti-PD-1 or anti-PD-L1 antibodies, which are immunotherapy drugs, these activated macrophages infiltrate to the brain, and the effect of treating Alzheimer's disease by directly removing amyloid-beta by macrophages has been confirmed.

Our immunotherapeutic drug CB201 while being developed by targets immune cells in the brain and has been confirmed to have an effect of activating immune cells in an Alzheimer's disease-induced animal model. It has been confirmed that T cells, which are immune cells, are activated and the number of macrophages is increased, these activated immune cells remove Alzheimer's-causing substances accumulated in the brain, thereby treating Alzheimer and showing efficacy to improve memory and behavior. In vivo experiments, our immunotherapeutic drug CB201 restored the Alzheimer's disease model to 85% of that of normal mice in the 'Y-maze experiment (Y-maze), and it was verified that the decline of cognition, memory, and behavioral abilities due to Alzheimer's dementia were restored to almost the same level as normal mice by improving to 106% compared to normal mice in the Morris water maze experiment (Morris water maze).